They exhibited potent dual antitumor activities against various types of cancer cells by mediating target cell apoptosis through activation of the death receptor–dependent pathway as well as T cell–mediated cytolysis upon binding of the TRAIL-R1 antigen presented on the target cell surface. This evidence concerns the gene TNFRSF10A and cancer.